Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer
Open Access
- 10 September 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (9) , 2694
Abstract
CD46 is generally overexpressed in many human cancers, representing a prime target for CD46-binding adenoviruses (Ads). This could help to overcome low anti-tumoral activity by coxsackie-adenoviral receptor (CAR)-targeting cancer gene therapy viruses. However, because of scarce side-by-side information about CAR and CD46 expression levels in cancer cells, mixed observations of cancer therapeutic efficacy have been observed. This study evaluated Ad-mediated therapeutic efficacy using either CAR-targeting Ad5 or CD46-targeting Ad5/35 fiber chimera in bladder cancer cell lines. Compared with normal urothelia, bladder cancer tissue generally overexpressed both CAR and CD46. While CAR expression was not correlated with disease progression, CD46 expression was inversely correlated with tumor grade, stage, and risk grade. In bladder cancer cell lines, expression levels of CD46 and CAR were highly correlated with Ad5/35- and Ad5-mediated gene transduction and cytotoxicity, respectively. In a human EJ bladder cancer xenograft mouse model, with either overexpressed or suppressed CD46 expression levels, Ad5/35-tk followed by ganciclovir (GCV) treatment significantly affected tumor growth, whereas Ad5-tk/GCV had only minimal effects. Overall, our findings suggest that bladder cancer cells overexpress both CAR and CD46, and that adenoviral cancer gene therapy targeting CD46 represents a more suitable therapy option than a CAR-targeting therapy, especially in patients with low risk bladder cancers.Keywords
Funding Information
- National Research Foundation of Korea (2011-0030132, 2016R1D1A3B04933830)
- Chonnam National University Hwasun Hospital Institute for Biomedical Science (HCRI17904-22)
This publication has 58 references indexed in Scilit:
- Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the Membrane Cofactor CD46 Triggers InfectionJournal of Virology, 2012
- Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancerGene Therapy, 2012
- Oncolytic Viruses in the Treatment of Bladder CancerAdvances in Urology, 2012
- Best practice in the treatment of nonmuscle invasive bladder cancerTherapeutic Advances in Urology, 2011
- Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial JunctionsJournal of Virology, 2011
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Nature Medicine, 2010
- Serotype Chimeric Human Adenoviruses for Cancer GeneTherapyViruses, 2010
- Treatment of medulloblastoma with a modified measles virusNeuro-Oncology, 2010
- Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic AdenovirusesCancer Research, 2009
- Four Viruses, Two Bacteria, and One Receptor: Membrane Cofactor Protein (CD46) as Pathogens' MagnetJournal of Virology, 2004